Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016

BACKGROUND: Despite evidence shown of dolutegravir (DTG)-related neurotoxicity, which may be more common when combined with abacavir (ABC), its reversibility has not been explored in a clinical trial. METHODS: We conducted a randomized, multicenter, open-label, pilot trial to evaluate the reversibil...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez Valero, Ignacio, Cabello, Alfonso, Ryan, Pablo, De La Fuente-Moral, Sara, Santos, Ignacio, Vivancos, Maria Jesus, Gonzalez, Alicia, Gorgolas, Miguel, Cuevas, Guillermo, Diaz De Santiago, Alberto, Cano, Joanna, Rua, Guadalupe, Yllescas, Maria, González García, Juan Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727346/
https://www.ncbi.nlm.nih.gov/pubmed/33335931
http://dx.doi.org/10.1093/ofid/ofaa482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727346/
https://www.ncbi.nlm.nih.gov/pubmed/33335931
http://dx.doi.org/10.1093/ofid/ofaa482

Ejemplares similares